Sequenom to Launch VisibiliT for Average-Risk Pregnancies Outside US, Expand MaterniT21 Plus | GenomeWeb

NEW YORK (GenomeWeb) – Sequenom next month plans to launch in international markets a second noninvasive prenatal test, called VisibiliT, that targets women with average-risk pregnancies and has both lower cost and content than its existing MaterniT21 Plus test,. The firm will also further expand MaterniT21 Plus, which it offers for increased-risk pregnancies, to include three additional clinically relevant microdeletions.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.